Analysts expect Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings per share (EPS) of ($0.38) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Genocea Biosciences’ earnings. The lowest EPS estimate is ($0.46) and the highest is ($0.30). Genocea Biosciences reported earnings per share of ($0.56) in the same quarter last year, which would indicate a positive year-over-year growth rate of 32.1%. The business is expected to report its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that Genocea Biosciences will report full-year earnings of ($2.09) per share for the current year. For the next fiscal year, analysts forecast that the firm will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.63) to ($0.80). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Genocea Biosciences.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.08). During the same quarter in the previous year, the business earned ($0.45) earnings per share.

Several research analysts recently commented on GNCA shares. Stifel Nicolaus downgraded Genocea Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $15.00 to $2.50 in a research note on Monday, September 25th. Cowen reaffirmed a “buy” rating and issued a $10.00 target price on shares of Genocea Biosciences in a research note on Tuesday, September 26th. Needham & Company LLC downgraded Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. ValuEngine downgraded Genocea Biosciences from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 26th. Finally, Zacks Investment Research raised Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Monday, October 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.25.

Several institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth $265,000. State Street Corp increased its stake in shares of Genocea Biosciences by 1,595.2% in the 2nd quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock worth $1,912,000 after acquiring an additional 344,572 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Genocea Biosciences in the 2nd quarter worth $204,000. Vanguard Group Inc. increased its stake in shares of Genocea Biosciences by 13.9% in the 2nd quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock worth $4,472,000 after acquiring an additional 104,790 shares during the last quarter. Finally, Northern Trust Corp increased its stake in shares of Genocea Biosciences by 642.9% in the 2nd quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock worth $1,601,000 after acquiring an additional 265,328 shares during the last quarter. 34.69% of the stock is owned by institutional investors and hedge funds.

Genocea Biosciences (NASDAQ:GNCA) opened at $1.08 on Wednesday. Genocea Biosciences has a 52 week low of $1.01 and a 52 week high of $7.29. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of 2.51. The company has a market capitalization of $31.00, a price-to-earnings ratio of -0.50 and a beta of 1.94.

TRADEMARK VIOLATION WARNING: “Brokerages Expect Genocea Biosciences Inc (GNCA) to Announce -$0.38 EPS” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/17/brokerages-expect-genocea-biosciences-inc-gnca-to-announce-0-38-eps.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.